Assignee
ASKGENE PHARMA INC
US·10 granted patents·17 pending applications·33 citations·filing 2015–2024
Top patents by PatentIndex Score
27 records- 0195US11746147B2Angiopoietin 2, VEGF dual antagonistsASKGENE PHARMA INC·Filed 2020·Granted Sep 5, 2023·4 cites·5 claims
- 0293US11059885B2Angiopoietin 2, VEGF dual antagonistsASKGENE PHARMA INC·Filed 2019·Granted Jul 13, 2021·7 cites·7 claims
- 0393US10654922B2Angiopoietin 2, VEGF dual antagonistsASKGENE PHARMA INC·Filed 2017·Granted May 19, 2020·8 cites·7 claims
- 0488US12043662B2Angiopoietin 2, VEGF dual antagonistsASKGENE PHARMA INC·Filed 2021·Granted Jul 23, 2024·1 cites·2 claims
- 0587US10077308B2PD-L1 specific monoclonal antibodies for disease treatment and diagnosisASKGENE PHARMA INC·Filed 2017·Granted Sep 18, 2018·6 cites·14 claims
- 0686US11845801B2IL-15 prodrugs and methods of use thereofASKGENE PHARMA INC·Filed 2020·Granted Dec 19, 2023·2 cites·21 claims
- 0785US11505618B2Antibodies and methods for making and using the sameASKGENE PHARMA INC·Filed 2019·Granted Nov 22, 2022·2 cites·16 claims
- 0883US10287336B2Feline erythropoietin receptor agonistsASKGENE PHARMA INC·Filed 2015·Granted May 14, 2019·3 cites·7 claims
- 0980US2025188160A1Novel angiopoietin 2, vegf dual antagonistsASKGENE PHARMA INC·Filed 2024·Application pending·0 cites
- 1078US2024101655A1Novel Angiopoietin 2, VEGF Dual AntagonistsASKGENE PHARMA INC·Filed 2023·Application pending·0 cites
- 1175US12312413B2Antibodies and methods for making and using the sameASKGENE PHARMA INC·Filed 2022·Granted May 27, 2025·0 cites·14 claims
- 1272US2025127858A1Novel cytokine prodrugsASKGENE PHARMA INC·Filed 2024·Application pending·0 cites
- 1369US2024067739A1Novel il-15 prodrugs and methods of use thereofASKGENE PHARMA INC·Filed 2023·Application pending·0 cites
- 1460US2019248858A1Novel feline erythropoietin receptor agonistsASKGENE PHARMA INC·Filed 2019·Application pending·0 cites
- 1559US2024076331A1Chimeric Molecules Comprising an IL-10 or TGF-Beta Agonist PolypeptideASKGENE PHARMA INC·Filed 2022·Application pending·0 cites
- 1658US2024076355A1Interferon Prodrugs and Methods of Making and Using the SameASKGENE PHARMA INC·Filed 2022·Application pending·0 cites
- 1757US2021260163A1Novel cytokine prodrugsASKGENE PHARMA INC·Filed 2019·Application pending·0 cites
- 1853US2025051413A1Chimeric molecules comprising il-12 agonist polypeptideASKGENE PHARMA INC·Filed 2022·Application pending·0 cites
- 1951US2023135521A1Pharmaceutical formulations for novel feline erythropoietin receptor agonistsASKGENE PHARMA INC·Filed 2019·Application pending·0 cites
- 2049US2022289822A1Novel il-21 prodrugs and methods of use thereofASKGENE PHARMA INC·Filed 2020·Application pending·0 cites
- 2149US2022306714A1Il-2 fusion proteins that preferentially bind il-2ralphaASKGENE PHARMA INC·Filed 2020·Application pending·0 cites
- 2247US2022356221A1Cytokine prodrugs and dual-prodrugsASKGENE PHARMA INC·Filed 2020·Application pending·0 cites
- 2346US12459980B2IL-21 prodrugs and methods of use thereofASKGENE PHARMA INC·Filed 2019·Granted Nov 4, 2025·0 cites·25 claims
- 2446US2019106494A1PD-L1 Specific Monoclonal Antibodies for Disease Treatment and DiagnosisASKGENE PHARMA INC·Filed 2018·Application pending·0 cites
- 2544US2018009869A1Fusion Protein Comprising Leptin and Methods for Producing and Using the SameASKGENE PHARMA INC·Filed 2017·Application pending·0 cites
- 2642US2018055944A1Novel antibody-albumin-drug conjugates (aadc) and methods for using themASKGENE PHARMA INC·Filed 2017·Application pending·0 cites
- 2738US2016137712A1Fusion Proteins With Dual Receptor Agonist ActivitiesASKGENE PHARMA INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ASKGENE PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →